Navigation Links
Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
Date:9/16/2008

ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed

at Improving Glycemic Control in Adults With Type 2 Diabetes

JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announced today that it has launched pre-clinical trials of ORMD 0901, a GLP1-analog.

ORMD 0901 belongs to the Incretin family of drugs which helps to manage diabetes, including reduction in blood glucose levels and inhibiting glucagon secretion.

Incretins have been cited in causing regeneration of pancreatic insulin secreting cells, and in tissue protective properties including protection of the heart. GLP1 and analogs are associated with gradual weight loss, which is very desirable in diabetes patients.

"The launch of pre-clinical trials of ORMD 0901 and expansion of Oramed's platform marks the next strategic milestone for our company as we demonstrate the effectiveness of our oral delivery technology in yet another important family of polypeptide drugs for diabetes, that are until now only available in injection form," said Oramed CEO Nadav Kidron.

We plan to conduct the ORMD 0901 trials at Hadassah University Medical Center and they are expected to conclude by the end of 2008.

Oramed plans to launch phase 2b trials of ORMD 0801, its oral insulin capsule, in India in the first quarter of 2009.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Eric Rosenberg

Cell: +972-54-566-7713

Office: +972-2-566-0001

Email: eric@oramed.com

Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-467-6950

Office: +972-2-589-2003

Email: matthew@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)...  The Corporate Whistleblower Center is urging ... anytime at 866-714-6466 if they possess proof a pharmaceutical company ... Aside from the innocent patients frequently being the victims, these types ... practices target Medicare recipients or the elderly. ... ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward ... comments on social media that offer a rare glimpse into the mind of those ... and New York Times bestselling author, has described people with ADHD as having “Ferrari ...
(Date:12/7/2016)... Hollywood, Fl (PRWEB) , ... December 07, 2016 , ... When it came time to ... new heart. Just 40 minutes later, the Pediatric Heart Transplant team at Joe ... true making the Weston teen the hospital’s 30th heart transplant recipient. , “He was ...
(Date:12/7/2016)... ... 07, 2016 , ... Baciocco Brothers Insurance Agency, a northern ... Sacramento/Folsom region, is initiating a charity event to raise support and awareness for ... treatment center in Sacramento works to provide area teens and families with treatment ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving ... are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... to the children of the world. , In exchange for generous donations, customers will ...
(Date:12/7/2016)... ... 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... of America, declared on her radio program in November 2016 the need to educate ... bullies attack leaders in corporate America, they are trying to take advantage of successful ...
Breaking Medicine News(10 mins):